2021年全球健康和生物科技投资报告（英）-40页_14mb

Global Health & Biotech Investment Summary

Core Content

The document provides an update on the global healthtech and biotech investment landscape as of March 2022, highlighting the rapid growth and transformative potential of these sectors. It also announces the EMERGE GHI investment forum, scheduled for March 15-16, 2022, in Dubai, which aims to connect health-tech innovators and investment leaders from the Gulf and around the world.

Key Highlights

Global Healthtech Overview

• Market Growth: The global healthtech market has reached a combined enterprise value of $1.7 trillion, a 5.5x increase since 2016.

• Record Investment: In 2021, healthtech investment hit $45 billion, with the three highest quarters ever recorded.

• Top Healthtech Companies:

  • Illumina: $64.2B (DNA sequencing)
  • Dexcom: $51.2B (Continuous glucose monitoring)
  • Veeva Systems: $43.9B (Cloud solutions)
  • JD Health: $32.4B (Online pharmacy)
  • Teladoc: $20.9B (Virtual care and telehealth)
  • Insulet: $20.0B (Insulin delivery system)
  • Ginkgo Bioworks: $20.0B (Biological engineering)
  • Exact Sciences: $16.1B (Cancer solutions)
  • GoodRx: $16.0B (Drug discount and telehealth)

• Unicorns: In 2021, 61 new healthtech unicorns were announced, reaching $1B+ valuation. The total number of healthtech and biotech unicorns since 2000 is 179 and 166, respectively.

• Market Trends:

  • Investment is expanding beyond telehealth to areas like remote monitoring, AI-first products, digital therapeutics, and femtech.
  • Digital health is now a $350 billion market, projected to grow to $600 billion.
  • Healthcare digitization is lagging compared to other sectors, with 70% of American hospitals still using fax for patient records.
  • Prevention and well-being are gaining traction as key strategies to reduce healthcare costs.

• Opportunities: There is a significant opportunity for healthcare innovation to eliminate inefficiencies and improve outcomes. The Gulf region is emerging as a key player in the global healthtech ecosystem, with governments and investors committing hundreds of millions to R&D and digital healthcare initiatives.

Global Biotech Overview

• Market Growth: The global biotech market has reached a combined enterprise value of $2.0 trillion, a 5.4x increase since 2016.

• Record Investment: In 2021, biotech investment hit $34 billion, with the three highest quarters ever recorded.

• Top Biotech Companies:

  • Moderna: $184B (mRNA platform)
  • BioNTech: $85B (mRNA platform)
  • Agilent: $46B (Laboratory solutions)
  • Alexion Pharmaceuticals: $40B (Rare diseases)
  • BeiGene: $33B (Immuno-oncology drugs)
  • Genmab: $30B (Oncology)
  • Alnylam Pharmaceuticals: $24B (RNAi therapeutics)
  • 10X Genomics: $17B (Scientific discovery)
  • Argon-X: $17B (Antibody-based drugs)
  • Incyte: $15B (Oncology)

• Unicorns: In 2021, 23 new biotech unicorns were created, reaching $1B+ valuation.

• Market Trends:

  • mRNA technology is becoming a key innovation, with applications beyond the pandemic (e.g., vaccines for CMV, Zika, and personalized cancer vaccines).
  • AI advancements are accelerating drug discovery and development, with 180+ AI-based solutions in the pipeline.
  • Biotech startups are experiencing longer cashburn periods but are becoming more efficient due to AI and experienced talent.

• Regional Growth:

  • Asia is growing faster than the US and China, with countries like the Netherlands, China, and India seeing higher investment growth.
  • US remains the largest market, but global distribution is increasing, with emerging markets offering untapped opportunities.

Key Points

• EMERGE GHI is a pivotal event in the Gulf region, aiming to drive innovation and investment in healthtech.
• The Gulf region is making significant strides in supporting health-tech startups with government backing and investment momentum.
• Digital health is becoming a necessity, not just a convenience, driven by Covid-19's impact and the need for efficiency.
• Femtech has significant potential, particularly in emerging markets, where it can address systemic biases and offer new market opportunities.
• The healthcare industry is shifting from treatment-focused to prevention and well-being driven by AI, data, and digital platforms.

Conclusion

The healthtech and biotech sectors are experiencing record investment and valuation growth, with innovation at the forefront. The Gulf region is emerging as a key player in this global shift, supported by government initiatives and investment. As the industry evolves, digital solutions, AI, and preventive care are expected to play a central role in shaping the future of healthcare.